Dr. Vipul Wayal | Metabolic Diseases, Immunology and Pharmacology | Best Researcher Award

Postdoctoral Researcher at Tunghai University, Taiwan

Dr. Vipul Rohidas Wayal is a dedicated and ambitious researcher specializing in Biotechnology, Translational Medicine, and Pharmaceutical Science. Currently serving as a Postdoctoral Researcher at Tunghai University, Taiwan, Dr. Wayal demonstrates a profound commitment to advancing scientific knowledge through innovative research on bioactive peptides, metabolic disorders, and drug delivery systems. His expertise extends across multiple scientific domains, including bioinformatics, molecular docking, animal modeling, and advanced drug formulation, making significant contributions to the field of life sciences.

Profile

ORCID

Scopus

Education

Dr. Wayal embarked on his academic journey with a Bachelor of Pharmacy in Pharmaceutical Sciences from Savitribai Phule Pune University, India, where he completed a thesis on the wound healing activity of herbal extracts. He further specialized by earning a Master of Pharmacy in Pharmaceutics from Rajiv Gandhi University of Health and Science, Bangalore, India, focusing on silk protein-based topical film-forming sprays for wound healing. Driven by his passion for research, he pursued doctoral studies in Animal Science and Biotechnology at Tunghai University, Taiwan. His Ph.D. thesis investigated the ameliorative effects of bioactive oligopeptides on metabolic-associated fatty liver disease (MAFLD) using murine models, under the guidance of Prof. Dr. Chang-Chi Hsieh.

Experience

Dr. Wayal’s professional career reflects a progressive trajectory in research and industrial management. As a Postdoctoral Researcher at Tunghai University since April 2024, he is engaged in developing novel fermented soybean products with cardiovascular protective functions and evaluating immunomodulatory functions of nutraceutical products. His research also involves the isolation, in-silico analysis, and animal modeling of bioactive proteins and peptides targeting metabolic diseases like NAFLD, T2DM, and atherosclerosis. Previously, he held positions as Factory Manager at Equine Nutrients, R&D Production Manager at Fibroheal Woundcare Pvt. Ltd., and Manufacturing Officer at Fresenius Kabi India Pvt. Ltd., gaining extensive experience in manufacturing, production management, and quality control within pharmaceutical and nutraceutical industries.

Research Interest

Dr. Wayal’s research interests are centered around the therapeutic potential of bioactive peptides and proteins, particularly their role in mitigating metabolic disorders. His work delves into the molecular mechanisms underlying MAFLD, hepatic steatosis, and liver injuries, with a focus on pathways like NLRP3 inflammasome activation, TLR4/NF-\u03baB signaling, and Keap1/Nrf2/HO-1 signaling. His expertise extends to bioinformatics, molecular dynamics simulations, plasmid preparation, cell culture, immunological assays, advanced imaging techniques, and chromatographic methods. His multidisciplinary approach enables him to translate bench research into potential clinical and commercial applications.

Award

In recognition of his innovative research, Dr. Wayal has received several honors, including the Excellent Idea Certificate for his patent on novel small molecule peptides targeting metabolic-associated fatty liver disease. His academic excellence was further acknowledged with the Tunghai University International Student Scholarship for two consecutive years (2021-2023), reflecting his outstanding performance and contribution to scientific research.

Publication

Dr. Wayal has made impactful contributions to scientific literature with several peer-reviewed publications:

1. Wayal V, Wang SD, Hsieh CC. Novel bioactive peptides alleviate Western diet-induced MAFLD in C57BL/6J mice by inhibiting NLRP3 inflammasome activation and pyroptosis via TLR4/NF-\u03baB and Keap1/Nrf2/HO-1 signaling pathways. Int. Immunopharmacol. 148 (2025): 114177.
2. Huang YL, Wayal V, Lin WC, Hsieh CC. Immunomodulatory effects of type II arabinogalactans fraction from Anoectochilus formosanus in a murine model of OVA-induced airway hyperresponsiveness. Carbohydr. Polym. Technol. App. 10 (2025): 100847.
3. Shao CH, Wayal V, Hsieh CC. Goat whey protein hydrolysate mitigates high-fructose corn syrup-induced hepatic steatosis in a murine model. Nutrients. 17 (2025).
4. Wayal V, Tsai ZE, Lin YH, Lai YH, Wang SD, Hsieh CC. Chicken meat hydrolysate improves acetaminophen-induced liver injury by alleviating oxidative stress via modulation in Keap1/Nrf2/HO-1 signaling in BALB/c mice. J. Agric. Food Res. 21 (2025): 101863.
5. Wayal V, Hsieh CC. Bioactive dipeptides mitigate high-fat and high-fructose corn syrup diet-induced metabolic-associated fatty liver disease via upregulation of Nrf2/HO-1 expressions in C57BL/6J mice. Biomed. Pharmacother. 168 (2023): 115724.

These publications have attracted attention in the field, with multiple citations in related articles, underscoring the relevance of his research.

Conclusion

Dr. Vipul Wayal exemplifies a dynamic and forward-thinking researcher whose multidisciplinary expertise bridges pharmaceutical sciences and biotechnology. His innovative research on bioactive peptides and their therapeutic potential positions him as a promising leader in combating metabolic diseases. With a robust academic foundation, substantial industrial experience, significant scholarly contributions, and a portfolio of patents and awards, Dr. Wayal is highly suitable for recognition through the Best Researcher Award nomination.